Skip to Content
Morningstar

Royalty Pharma PLC Class A RPRX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$28.11 +0.13 (0.46%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Royalty Pharma's Diverse Portfolio Supports Long-Term Growth

Rachel Elfman,

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company makes lump-sum payments in exchange for future cash flows linked to those products’ sales revenue, which differentiates it from other biotech companies that are exposed to high R&D and/or manufacturing costs. Its uniqueness also lies in the diversity of royalties across different therapeutic areas. This stands in contrast to a typical biotech firm’s focus on developing specialized therapies targeting certain diseases.

Read Full Report

Price vs Fair Value

View History
RPRX is trading at a 47% discount.
Price
$27.82
Fair Value
$69.00
Uncertainty
Medium
1-Star Price
$77.60
5-Star Price
$52.60
Economic Moat
Rypcct
Capital Allocation
Jjzvmfghr

Bulls Say, Bears Say

Bulls

Royalty Pharma’s portfolio includes market-leading therapies for a wide range of diseases, enabling stable future royalty streams and high returns on investments over the next decade.

Bears

Underperformance of key portfolio products due to major regulatory changes could put pressure on Royalty Pharma’s cash flows.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPRX is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$27.98
Day Range
$27.65–28.21
52-Week Range
$25.92–35.76
Bid/Ask
$27.55 / $28.92
Market Cap
$12.56 Bil
Volume/Avg
3.3 Mil / 2.9 Mil

Key Statistics

Price/Earnings (Normalized)
16.95
Price/Sales
7.20
Dividend Yield (Trailing)
2.88%
Dividend Yield (Forward)
2.99%
Total Yield
5.33%

Company Profile

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Value
Total Number of Employees
89
Website
https://www.royaltypharma.com

Competitors

Valuation

View More
Metric
RPRX
VRTX
PFE
Price/Earnings (Normalized)
 16.9526.1313.73
Price/Book Value
 1.925.831.60
Price/Sales
 7.2010.502.44
Price/Cash Flow
 5.6827.2413.11
Price/Earnings
RPRX
VRTX
PFE

Financial Strength

Metric
RPRX
VRTX
PFE
Quick Ratio
 7.873.600.58
Current Ratio
 7.903.990.91
Interest Coverage
 9.7086.380.74
Quick Ratio
RPRX
VRTX
PFE

Profitability

Metric
RPRX
VRTX
PFE
Return on Assets (Normalized)
 −4.87%19.46%4.98%
Return on Equity (Normalized)
 −13.28%25.47%10.90%
Return on Invested Capital (Normalized)
 −4.22%21.34%7.28%
Return on Assets
RPRX
VRTX
PFE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRQvqwkwcfrDxv$554.7 Bil
VRTX
Vertex Pharmaceuticals IncNnnjykrnRzcpvy$103.6 Bil
REGN
Regeneron Pharmaceuticals IncMrgttpcZcqsqwd$97.8 Bil
MRNA
Moderna IncCxnkjgzpmPlmp$38.8 Bil
ARGX
argenx SE ADRMfrbvcnJyk$22.0 Bil
BNTX
BioNTech SE ADRLyfsxvsxxGblsr$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncKqdrgtfbWsjhhf$18.2 Bil
BMRN
Biomarin Pharmaceutical IncVpqszxmhbHjltql$17.3 Bil
INCY
Incyte CorpKqzypjxxsTsgnrt$11.5 Bil

Sponsor Center